c****g
发帖数: 37081 | 1 paclitaxel. 中医可没说过啃树皮。中医永远不可能发现taxanes 。 |
|
H**p
发帖数: 2504 | 2 Unbelievable, aided by Taxan's penalties. |
|
|
|
|
P*******e
发帖数: 39399 | 6 taxans需要进攻HC 需要个靠谱的DC就行
选lovie smith真是浪费进攻人才 |
|
a********l
发帖数: 39524 | 7 不会在休斯敦大学的那个体育场吧？还是在taxans的大体育场？ |
|
s****r
发帖数: 736 | 8 筛选某种表达taxol的微生物是可能的
表达水平，现在这个值还是低 （448.52 ug/L)。当然比起单纯从紫杉里提取的量，那还是可观的。但是这个值有没有夸大，就另说了。
btw, 他们那些提高表达水平的手段还是太传统了
以下是1993的science paper
Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of
Pacific yew
Science, Vol. 260 no. 5105 pp. 214-216
http://www.sciencemag.org/content/260/5105/214.abstract?sid=7940a3e5-a67d-4b47-9975-2154e1a66c03
最近的science paper
Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in
Escherichia coli
Science, Vol. 330 no. 6000 pp. 70-74
h... 阅读全帖 |
|
y*****l
发帖数: 5997 | 9 来自主题: _pennystock版 - SPPI Spectrum Pharmaceuticals Announces ZEVALIN(R) and Belinostat Abstracts to Be
Presented at the American Society of Clinical Oncology Annual Meeting
4 hours 16 minutes ago - BIZ via Comtex
BusinessWireSpectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development operations
with a primary focus in oncology, today announced ZEVALIN(R) (ibritumomab
tiuxetan) and Belinostat abstracts will be presented at the 2011 Annual
Meeting of the American... 阅读全帖 |
|
E****e
发帖数: 315 | 10 from SeekingAlpha
The recent news announcing Genentech’s (DNA) receipt of a “Refuse to File
(RTF)” letter from the FDA for the accelerated approval of the Biologic
License Application (BLA) for trastuzumab-DM1 (T-DM1) has caused a sell-off
in Immunogen, the owner of the technology and partner on the drug with Roche
. According to the FDA letter, the refusal to give the early approval was
because “the trials had not yet exhausted all available drugs approved for
metastatic breast cancer, regardle... 阅读全帖 |
|
E****e
发帖数: 315 | 11 from SeekingAlpha
The recent news announcing Genentech’s (DNA) receipt of a “Refuse to File
(RTF)” letter from the FDA for the accelerated approval of the Biologic
License Application (BLA) for trastuzumab-DM1 (T-DM1) has caused a sell-off
in Immunogen, the owner of the technology and partner on the drug with Roche
. According to the FDA letter, the refusal to give the early approval was
because “the trials had not yet exhausted all available drugs approved for
metastatic breast cancer, regardle... 阅读全帖 |
|
m****g
发帖数: 530 | 12 BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Mar 31, 2010 - Genta Incorporated (
OTCBB: GETA) today
announced that the Company has initiated a confirmatory Phase 2b trial of
tesetaxel in patients with
advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage
small molecule. As a late Phase
2 oncology product, tesetaxel is the leading oral taxane currently in
clinical development. The trial is
currently open to enrollment at Northwestern University, Chicago, IL, which
will be joined b |
|
